EuroBiotech—More articles of note

Newspapers
(NS Newsflash/CC BY 2.0)

> Innate Pharma agreed to trial anti-C5aR monoclonal antibody IPH5401 in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi. The phase 1/2 trial will assess the effect of the combination in patients with certain types of solid tumors. Statement

> BerGenBio posted data from phase 2 trials that are administering its AXL inhibitor in combination with Merck’s Keytruda. Release 

> Helsinn Healthcare joined with Scientific Centre of Monaco to develop pharmacological inhibitors in kidney cancer. Release 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sanofi filed for European approval of a sleeping sickness treatment. The French pharma worked on the therapy with the Drugs for Neglected Disease Initiative. Statement

> Affimed shared data from a trial that tested NK cell engager candidate AFM13 in combination with Keytruda. Statement

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.